|
|
 Previous Article | Table of Contents | Next Article 
Assay of prekallikrein in human plasma: comparison of amidolytic,
esterolytic, coagulation, and immunochemical assays
CA Fisher, AH Schmaier, VP Addonizio and RW Colman
Using the substrate H-D-Pro-Phe-Arg-p-nitroanilide-HCl, an amidolytic assay
was designed to measure prekallikrein in plasma. At a substrate
concentration of 1 mM (Km = 0.2 mM), the amidolysis of purified kallikrein
at 1 coagulant unit/ml was observed to be 2.47 mumole/min/ml. Conditions
for plasma prekallikrein activation were optimized to approach complete
activation when compared to the amidolytic activity of the purified plasma
kallikrein. Plasma treated with chloroform to destroy inhibitors of
kallikrein was activated with dilute kaolin (final concentration 1 mg/ml)
for 1 min at 25 degrees C. Activated plasma prekallikrein had 78% (1.92
mumole/min/ml) of activity of purified kallikrein at plasma concentration.
Comparison of this amidolytic assay with immunochemical, esterolytic, and
coagulant assays of three subject populations (normals, women on birth
control pills, and patients with hepatocellular disease) showed good
correlation both in normals and in the patient groups between the
amidolytic and esterolytic assays (r = 0.89). Each enzymatic assay
correlated with the immunochemical assay (r = 0.72, r = 0.68,
respectively). However, comparison of each of these assays with the
coagulant assay showed no significant correlation due to the large inherent
error of the latter assay. This standardized plasma prekallikrein
amidolytic assay should facilitate studies of plasma prekallikrein
concentration in physiologic and pathologic conditions and help identify
activation of the contact phase of coagulation in disease states.
Volume 59,
Issue 5,
pp. 963-970,
05/01/1982
Copyright © 1982 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. R. Baird and P. N. Walsh
Factor XI, but Not Prekallikrein, Blocks High Molecular Weight Kininogen Binding to Human Umbilical Vein Endothelial Cells
J. Biol. Chem.,
May 30, 2003;
278(23):
20618 - 20623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Jaffa, R. Durazo-Arvizu, D. Zheng, D. T. Lackland, S. Srikanth, W. T. Garvey, and A. H. Schmaier
Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes
Diabetes,
May 1, 2003;
52(5):
1215 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Motta, R. Rojkjaer, A. A.K. Hasan, D. B. Cines, and A. H. Schmaier
High Molecular Weight Kininogen Regulates Prekallikrein Assembly and Activation on Endothelial Cells: A Novel Mechanism for Contact Activation
Blood,
January 15, 1998;
91(2):
516 - 528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Colman and A. H. Schmaier
Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes
Blood,
November 15, 1997;
90(10):
3819 - 3843.
[Full Text]
[PDF]
|
|
|
|
|
